The company hopes to build enrollment of men with advanced prostate cancer within its larger Strata Trial — which provides free targeted sequencing and tracks its impact on clinical trial enrollment.
The firm plans to develop and evaluate the utility of an ethnically diverse group of metastatic prostate cancer patient-derived xenograft models.
The study is part of an effort to drive health plan coverage for Exosome's ExoDx Prostate IntelliScore prostate cancer test.
The device allows researchers to track cancer growth for a longer period of time, enabling improved observations and analysis, according to the researchers.
Ambry will provide genetic testing in NorthShore’s Genomic Health Initiative in hopes of moving precision medicine into clinical practice.
The companies will market Angle's Parsortix system for harvesting circulating tumor cells with Qiagen's liquid biopsy product portfolio.
The company said the dramatic increase was driven by a one-time buy-out of patents related to colorectal cancer by Exact Sciences.
The genomic test is designed to help doctors decide which patients are at low enough risk that they can be more conservatively managed.
In Genome Biology this week: computational tool to uncover cancer driver mutations, microbial species linked to ankylosing spondylitis, and more.
Researchers identified shifts in regulatory features and enhanced NOTCH signaling pathway activation in prostate tumors containing a TMPRSS2-ERG2 gene fusion.
The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.
US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.
Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.
In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.